Caris Life Sciences to identify targets for Merck KGaA antibody-drug conjugates for cancer
April 5, 2024
Caris Discovery, the therapeutic research arm of Caris Life Sciences Inc., has established a multiyear strategic partnership with Merck KGaA to accelerate the discovery and development of first-in-class antibody-drug conjugates for cancer patients.